The aim of the study is to evaluate the effect of pantoprazole on fast symptom reduction in patients with NERD (non-erosive reflux disease) or eGERD (erosive gastroesophageal reflux disease) in clinical practice. During the study, the patients will complete a short version of a patient-orientated, self-assessed reflux questionnaire (ReQuest™ in Practice). The study will provide further data on...
Date First Received: November 12, 2007
Last Updated: July 14, 2008
Verified by: Nycomed, July 2008
Clinical Trial Phase: N/A | Start Date: November 2007
Overall Status: Recruiting
Estimated Enrollment: 2500
Brief Summary
Official Title: “Pantoprazole 20 mg/40mg for Gastroesophageal Reflux Disease (GERD).”
Condition Keyword(s):
Intervention(s):
The aim of the study is to evaluate the effect of pantoprazole on fast symptom reduction in patients with NERD (non-erosive reflux disease) or eGERD (erosive gastroesophageal reflux disease) in clinical practice. During the study, the patients will complete a short version of a patient-orientated, self-assessed reflux questionnaire (ReQuest™ in Practice). The study will provide further data on safety and tolerability of pantoprazole.
Study Type: Observational
Study Design: Case-Only, Prospective
Intervention(s) in this Clinical Trial
- Drug: Pantoprazole
- This is an observational study. Therefore, the physician decides about dosage according to individual needs.
Arms, Groups and Cohorts in this Clinical Trial
- : Panther
Outcome Measures for this Clinical Trial
Primary Measures
- To evaluate a short version of a patient-orientated, self-assessed reflux questionnaire in clinical practice (ReQuest™ in Practice)
- Time Frame: 7 days
- Time Frame: 7 days
Secondary Measures
- To survey epidemiological data for the prevalence of eGERD and NERD
- Time Frame: 7 days
- Time Frame: 7 days
Criteria for Participation in this Clinical Trial
Main inclusion criteria:
- eGERD (according to Los Angeles classification grade A-D)
- NERD
Main exclusion criteria:
- Hypersensitivity
- Co-administration with Atazanavir
- Pregnancy
- Other criteria as defined in the Summary of Product Characteristics (Fachinformation
- Chapter 4.3)
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 12 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: Nycomed
Overall Clinical Trial Officials and Contacts
Dr. Thomas D. Bethke, MD, MBA Study Director Nycomed Deutschland GmbH, 78467 Konstanz, Germany
Overall Contact: Nycomed Info clinicaltrials@nycomed.com
Additional Information
Information obtained from ClinicalTrials.gov on September 04, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00561730
Study ID Number: PAN 20/40 Panther 07/10
ClinicalTrials.gov Identifier: NCT00561730
Health Authority: Germany: Federal Institute for Drugs and Medical Devices
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
